Advertisement

High Levels of Saturated Fatty Acids may Exacerbate the Pathogenesis of Primary Sjögren’s Syndrome

  • Yosuke ShikamaEmail author
  • Naozumi Ishimaru
  • Yasusei Kudo
  • Rieko Arakaki
  • Yukiko Bando
  • Nanako Aki
  • Yoshio Hayashi
  • Makoto Funaki
Open Access
Conference paper

Abstract

Obesity and type 2 diabetes (T2D) are characterized by decreased insulin sensitivity and higher concentrations of free fatty acids (FFAs) in the serum. Among FFAs, saturated fatty acids, such as palmitate, have been reported to play a role in obesity-associated inflammation. Primary Sjögren’s syndrome (SS) is an autoimmune disease characterized by infiltration of inflammatory mononuclear cells and destruction of epithelial cells in salivary and lacrimal glands. Although epidemiological studies have suggested a link between primary SS and dyslipidemia or T2D, little is known about the clinical significance of elevated serum level of FFAs in primary SS. In salivary gland epithelial cells of patients with primary SS, interleukin (IL)-6 production and α-fodrin degradation are increased. IL-6 is one of the pro-inflammatory cytokines, and the cleavaged α-fodrin serves as an auto-antigen. In this study, we demonstrate that palmitate, but not unsaturated fatty acids, induces IL-6 production and α-fodrin degradation in human salivary gland epithelial cell lines. However, palmitate did not induce these responses in keratinocytes. Taken together, these results suggest that higher levels of saturated fatty acids may promote the severity of primary SS.

Keywords

Apoptosis Interleukin-6 Lipids Palmitate Sjögren’s syndrome α-fodrin 

18.1 Introduction

Obesity is rapidly prevailing and is one of the major threats to global health these days. The epidemic of obesity has resulted in dramatic increases in the prevalence of obesity-associated diseases including type 2 diabetes (T2D) [1]. It has been known that the level of free fatty acids (FFAs) in the blood is elevated in T2D patients as well as animal models of T2D [2], which is attributable to enhanced lipolysis in adipocytes and increased consumption of dietary lipids [3]. It has been demonstrated that saturated fatty acids (SFAs), such as palmitate and stearate, induce inflammatory responses presumably activation of Toll-like receptor (TLR) 4 and its downstream signaling pathway [4, 5, 6]. TLRs are one of the pattern recognition receptors that play a key role in induction of innate and adaptive immune response through recognition of pathogen-associated molecular patterns (PAMPs) of microbes [7]. Furthermore, excess amount of FFAs in the blood can lead to proinflammatory response and intracellular lipid accumulation, which could also result in cellular dysfunction, so-called ‘lipotoxicity’. Lipotoxicity has been reported in pancreatic β cells, hepatocytes, cardiomyocytes, and skeletal muscle cells [8], but hardly reported in epithelial cells such as epithelial cells in exocrine glands.

Primary Sjögren’s syndrome (SS) is an autoimmune disorder that is characterized by chronic dysfunction and destruction of exocrine glands, mainly the salivary and lacrimal glands associated with chronic lymphocytic infiltrating lesions, that leads to persistent dryness of eyes and mouth. Emerging evidence suggests that salivary gland epithelial cells also actively participate in the inflammatory process of SS [9]. For instance, interleukin (IL)-6, which is one of proinflammatory cytokines known to serve as a B cell growth factor and a vital factor for plasma cell survival [10], is upregulated in salivary gland epithelial cells of SS patients [11, 12, 13]. IL-6 production is induced by activation of intracellular signaling cascades including the mitogen-activated protein kinase (MAPK) pathways and the nuclear factor-κB (NF-κB) pathway [14]. It has been also reported that α-fodrin, which is a ubiquitously-expressed heterodimeric calmodulin-binding protein, is cleaved during apoptosis by caspase-3 or μ-calpain to produce 120 kDa fragments in salivary gland ductal epithelial cells. These α-fodrin-derived 120 kDa fragments have been shown to serve as an auto-antigen in murine and human primary SS [15, 16].

An association between obesity-related metabolic disorders and SS was first reported in “pseudo-Sjögren syndrome” [17, 18], which was followed by an experimental study in mice that reported a link between SS and diabetes [19]. Moreover, it was recently reported that primary SS patients had significantly higher incidence of metabolic disorders, such as T2D [20, 21]. These observations described above led us to hypothesize that SFAs may induce IL-6 secretion, lipotoxicity, and α-fodrin degradation in human salivary gland epithelial cells. In this report, we provide evidence that SFAs, but not unsaturated fatty acids, induce IL-6 secretion mediated by activation of p38 MAPK and NF-κB activation. Palmitate also induces intracellular lipid accumulation and apoptosis, and α-fodrin degradation. However, these SFAs-dependent responses observed in salivary gland epithelial cells are not common among epithelial cells in other type of tissues. These observations implicate that salivary gland epithelial cells are susceptible to palmitate-induced IL-6 secretion, lipotoxicity, and α-fodrin degradation, which could exacerbate the pathogenesis of primary SS in salivary glands.

18.2 Materials and Methods

18.2.1 Reagents

Fetal bovine serum (FBS) and penicillin/streptomycin were purchased from Life Technologies (Carlsbad, CA). Dulbecco’s modified Eagle’s medium (DMEM), FFAs, SP600125, SB203580, and BAY11-7082 were obtained from Sigma-Aldrich (St. Louis, MO). FFA-free bovine serum albumin (BSA) was obtained from Merck (Darmstadt, Germany). A stock solution of FFA was prepared and conjugated with BSA as described previously [22] with slight modifications as follows; FFA was dissolved at a concentration of 100 mM in 0.1 mol/L NaOH at 90 °C for 20 min, which was then diluted 10-fold with 10 % BSA solution pre-incubated at 55 °C. The solution was vortexed for 10 s and incubated at 55 °C for additional 10 min. FFA solution of 10 mmol/L FFA with 10 % BSA and 10%BSA control solutions were prepared just before experiments. FFA preparations were checked for LPS contamination using Limulus Color KY Single Test (Wako).

18.2.2 Antibodies

Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH), anti-IκBα, antiphospho-IκBα (Ser32/36), anti-p38 MAPK, antiphospho-p38 MAPK (Thr180/Tyr182), anti-SAPK/JNK, antiphospho-SAPK/JNK (Thr183/Tyr185), anti-caspase-3, and anti-calpain1 (μ-type) antibodies were purchased from Cell Signaling Technology (Danvers, MA). Anti-α-fodrin was obtained from Enzo Life Sciences (Plymouth Meeting, PA).

18.2.3 Cells and Cell Culture

A human parotid gland ductal epithelial cell line HSY and a human submandibular gland ductal epithelial cell line HSG were developed as described previously [23, 24]. A human oral squamous carcinoma cell line HSC-2 was provided by Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). An immortalized human keratinocyte cell line HaCaT was obtained from Dr. Norbert E. Fusenig (German Cancer Research Center, Heidelberg, Germany). Cells were cultured in DMEM supplemented with 10 % FBS, 100 U/mL penicillin and 100 μg/mL streptomycin at 37 °C with a humidified atmosphere of 5 % CO2. Cells were serum starved (0.1 % BSA) overnight for experiments.

18.2.4 RNA Isolation and RT-PCR

Cells were lysed in 1 mL of ISOGEN (Nippon Gene, Tokyo, Japan), and total RNA was extracted as described in the manufacturer’s instructions. One μg of total RNA was reverse transcribed into cDNA with a first-strand cDNA synthesis kit (Roche Diagnostics, Indianapolis, IN). Primers used were as follows: TLR4 (forward) 5′-TGGATACGTTTCCTTATAAG-3′ and (reverse) 5′-GAAATGGAGGCACCCCTTC-3′; IL-6 (forward) 5′-AAGCCAGAGCTGTGCAGATGAGTA-3′ and (reverse) 5′-TGTCCT GCAGCCACTGGTTC-3′; GAPDH (forward) 5′-GCCACATCGCTCAGACAC-3′ and (reverse) 5′-CTCGCTCCTGGAAGATGG-3′. PCR products were then subjected to agarose gel electrophoresis and analyzed with an LAS-3000 UV Lumino-image analyzer (Fujifilm, Tokyo, Japan).

18.2.5 Measurement of IL-6 Production

Cells were seeded into 96-well plates at a concentration of 1 × 105 cells/well (Orange Scientific, Braine-l’Alleud, Belgium) and incubated overnight. After treating the cells as described in the figure legends, the medium was collected. The amount of IL-6 in the medium was determined using a human IL-6 ELISA kit (Thermo Scientific, Rockford, IL) according to the manufacturer’s instructions.

18.2.6 Immunoblotting

After treating the cells as described in the figure legends, cells were rinsed three times with ice-cold phosphate-buffered saline (PBS) and lysed in radio-immunoprecipitation assay buffer [50 mM Tris, 150 mM NaCl, 1 % sodium deoxycholate, 1 % Triton X-100, 0.1 % sodium dodecyl sulfate, 1 mM sodium orthovanadate, and 1 % protease inhibitor cocktail (Sigma) (pH 7.5)]. Cell lysates obtained by centrifugation at 15,000 × g and 4 °C for 10 min were subjected to SDS-PAGE and transferred to polyvinylidene diflouride (PVDF) membranes as described previously [25]. In some experiments, antibodies were diluted in Can Get Signal (Toyobo, Osaka, Japan). Immunoblotting was performed with an ECL PLUS system according to the manufacturer’s instructions, and analyzed by a LAS-3000 UV Lumino-image analyzer (Fujifilm).

18.2.7 Oil Red O Staining

To evaluate intracellular lipid accumulation, cells were stained with Oil Red O as described previously [26]. Briefly, after treating the cells, cells were washed three times with iced PBS and fixed with 4 % paraformaldehyde. Fixed cells were washed again with PBS and stained with Oil Red O solution (1.8 mg/mL Oil Red O in 60 % ethanol) for 15 min at room temperature. After cells were washed again with PBS, cells were observed on a phase contrast microscope (Olympus, Tokyo, Japan).

18.2.8 Cell Viability Assay

Cell viability was assessed by measuring a mitochondrial activity in reducing 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt (WST-8) to formazan using a Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) according to the manufacturer’s instructions. The amount of formazan was quantified using a microplate reader (BioRad, Hercules, CA).

18.2.9 Annexin V-FITC/Propidium Iodide (PI) Staining

Palmitate-induced apoptosis of salivary gland cells was evaluated by an Annexin V-FITC/PI staining with a TACS Annexin V-FITC Apoptosis Detection Kit (R and D systems, Minneapolis, MN) according to the manufacturer’s instructions. After treating the cells as described in the figure legends, fluorescent-positive cells were detected by FACSVerse and analyzed by FACSuite (BD Biosciences, San Diego, CA).

18.2.10 DAPI Staining

For detecting apoptosis in HSY cells, they were seeded on Lab-Tek chamber slides (Nunc, Thermo Fisher Scientific, Rochester, NY). After treating the cells as described in the figure legends, cells were washed three times with iced PBS and fixed with 4 % paraformaldehyde followed by staining with 4′,6-diamidino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA). Stained cells were visualized on a laser scanning confocal microscope (Carl Zeiss, Gottingen, Germany). Apoptotic cells were morphologically defined as cells with nuclear shrinkage, condensation, and fragmentation.

18.2.11 Data Analysis

To confirm the reproducibility of the results, all experiments were conducted at least twice. Experimental values are given as mean ± standard deviation (SD). The statistical significance of differences was evaluated using a Student’s unpaired t-test or Dunnett’s multiple-comparison test after an analysis of variance (ANOVA) with IBM SPSS Statistics software 19.0 (IBM, Armonk, NY). P values less than 0.05 were considered to be significant.

18.3 Results and Discussion

We obtained results as described below. (a) Palmitate treatment induces IL-6 secretion in HSY and HSG cells, but not HaCaT cells. (b) In salivary gland epithelial cells, saturated fatty acids, but not unsaturated fatty acids, induces IL-6 secretion presumably through activation of NF-κB and p38 MAPK. (c) It has been documented that lipotoxicity causes apoptosis, which is featured by some morphological changes such as cell shrinkage, cell rounding, and lipid accumulation [8, 27]. Thus, we investigated whether or not palmitate treatment induces morphological changes. Palmitate treatment induced morphological changes which are cell rounding and lipid accumulation in HSY and HSG cells. On the other hand, HSC-2 and HaCaT cells failed to accumulate lipid droplet after palmitate treatment despite their tendency to round up (Fig. 18.1). (d) Palmitate treatment increases apoptosis of HGY and HSG cells. (e) Palmitate induces a-fodrin degradation and caspase-3 activation in salivary gland epithelial cells. Details were already shown in our report [28]. Moreover, we recently confirmed that, when model mice of primary SS were fed with high-fat diet to elevate the serum level of saturated fatty acids, their salivary glands and lacrimal glands exhibited inflammation significantly more advanced than those observed in model mice fed with normal diet (data not shown). Taken together, these results suggest that higher levels of saturated fatty acids may promote the severity of primary SS.
Fig. 18.1

HSY cells and HSG cells, but not HSC-2 cells and HaCaT cells, exhibited palmitate-induced cell shape change and lipid accumulation. A representative image (×400) of cells treated with control (BSA) or palmitate (500 μM) for 24 h. Arrow heads indicate cytoplasmic lipid droplets. Scale bars = 20 μm

In conclusion, our data indicate that palmitate may exacerbate the pathogenesis of primary SS. Results presented in this report should encourage further investigations on relationship between metabolic-related disorders and autoimmune diseases such as primary SS.

References

  1. 1.
    Hill JO. Understanding and addressing the epidemic of obesity: an energy balance perspective. Endocr Rev. 2006;27(7):750–61.PubMedCrossRefGoogle Scholar
  2. 2.
    Boden G. Interaction between free fatty acids and glucose metabolism. Curr Opin Clin Nutr Metab Care. 2002;5(5):545–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Cnop M. Fatty acids and glucolipotoxicity in the pathogenesis of type 2 diabetes. Biochem Soc Trans. 2008;36(Pt 3):348–52.PubMedCrossRefGoogle Scholar
  4. 4.
    Eguchi K, Manabe I, Oishi-Tanaka Y, Ohsugi M, Kono N, Ogata F, et al. Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. Cell Metab. 2012;15(4):518–33.PubMedCrossRefGoogle Scholar
  5. 5.
    Erridge C, Samani NJ. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler Thromb Vasc Biol. 2009;29(11):1944–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Maloney E, Sweet IR, Hockenbery DM, Pham M, Rizzo NO, Tateya S, et al. Activation of NF-kappaB by palmitate in endothelial cells: a key role for NADPH oxidase-derived superoxide in response to TLR4 activation. Arterioscler Thromb Vasc Biol. 2009;29(9):1370–5.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801.PubMedCrossRefGoogle Scholar
  8. 8.
    Kusminski CM, Shetty S, Orci L, Unger RH, Scherer PE. Diabetes and apoptosis: lipotoxicity. Apoptosis. 2009;14(12):1484–95.PubMedCrossRefGoogle Scholar
  9. 9.
    Manoussakis MN, Kapsogeorgou EK. The role of epithelial cells in the pathogenesis of Sjogren’s syndrome. Clin Rev Allergy Immunol. 2007;32(3):225–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol. 2002;169(8):4213–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Anaya JM, Talal N. Sjogren’s syndrome comes of age. Semin Arthritis Rheum. 1999;28(6):355–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Fox RI, Kang HI, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjogren’s syndrome. J Immunol. 1994;152(11):5532–9.PubMedGoogle Scholar
  13. 13.
    Sekiguchi M, Iwasaki T, Kitano M, Kuno H, Hashimoto N, Kawahito Y, et al. Role of sphingosine 1-phosphate in the pathogenesis of Sjogren’s syndrome. J Immunol. 2008;180(3):1921–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Ajibade AA, Wang Q, Cui J, Zou J, Xia X, Wang M, et al. TAK1 negatively regulates NF-kappaB and p38 MAP kinase activation in Gr-1 + CD11b + neutrophils. Immunity. 2012;36(1):43–54.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Haneji N, Nakamura T, Takio K, Yanagi K, Higashiyama H, Saito I, et al. Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren’s syndrome. Science. 1997;276(5312):604–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Miyazaki K, Takeda N, Ishimaru N, Omotehara F, Arakaki R, Hayashi Y. Analysis of in vivo role of alpha-fodrin autoantigen in primary Sjogren’s syndrome. Am J Pathol. 2005;167(4):1051–9.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Goldman JA, Julian EH. Pseudo-Sjogren syndrome with hyperlipoproteinemia. JAMA. 1977;237(15):1582–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Kaltreider HB, Talal N. Bilateral parotid gland enlargement and hyperlipoproteinemia. JAMA. 1969;210(11):2067–70.PubMedCrossRefGoogle Scholar
  19. 19.
    Robinson CP, Yamachika S, Alford CE, Cooper C, Pichardo EL, Shah N, et al. Elevated levels of cysteine protease activity in saliva and salivary glands of the nonobese diabetic (NOD) mouse model for Sjogren syndrome. Proc Natl Acad Sci U S A. 1997;94(11):5767–71.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Kang JH, Lin HC. Comorbidities in patients with primary Sjogren’s syndrome: a registry-based case–control study. J Rheumatol. 2010;37(6):1188–94.PubMedCrossRefGoogle Scholar
  21. 21.
    Ramos-Casals M, Brito-Zeron P, Siso A, Vargas A, Ros E, Bove A, et al. High prevalence of serum metabolic alterations in primary Sjogren’s syndrome: influence on clinical and immunological expression. J Rheumatol. 2007;34(4):754–61.PubMedGoogle Scholar
  22. 22.
    Cousin SP, Hugl SR, Wrede CE, Kajio H, Myers Jr MG, Rhodes CJ. Free fatty acid-induced inhibition of glucose and insulin-like growth factor I-induced deoxyribonucleic acid synthesis in the pancreatic beta-cell line INS-1. Endocrinology. 2001;142(1):229–40.PubMedGoogle Scholar
  23. 23.
    Shirasuna K, Sato M, Miyazaki T. A neoplastic epithelial duct cell line established from an irradiated human salivary gland. Cancer. 1981;48(3):745–52.PubMedCrossRefGoogle Scholar
  24. 24.
    Yanagawa T, Hayashi Y, Nagamine S, Yoshida H, Yura Y, Sato M. Generation of cells with phenotypes of both intercalated duct-type and myoepithelial cells in human parotid gland adenocarcinoma clonal cells grown in athymic nude mice. Virchows Arch B Cell Pathol Incl Mol Pathol. 1986;51(3):187–95.PubMedCrossRefGoogle Scholar
  25. 25.
    Shikama Y, Kuroishi T, Nagai Y, Iwakura Y, Shimauchi H, Takada H, et al. Muramyldipeptide augments the actions of lipopolysaccharide in mice by stimulating macrophages to produce pro-IL-1beta and by down-regulation of the suppressor of cytokine signaling 1 (SOCS1). Innate Immun. 2011;17(1):3–15.PubMedCrossRefGoogle Scholar
  26. 26.
    Lin CL, Huang HC, Lin JK. Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. J Lipid Res. 2007;48(11):2334–43.PubMedCrossRefGoogle Scholar
  27. 27.
    Maestre I, Jordan J, Calvo S, Reig JA, Cena V, Soria B, et al. Mitochondrial dysfunction is involved in apoptosis induced by serum withdrawal and fatty acids in the beta-cell line INS-1. Endocrinology. 2003;144(1):335–45.PubMedCrossRefGoogle Scholar
  28. 28.
    Shikama Y, Ishimaru N, Kudo Y, Bando Y, Aki N, Hayashi Y, et al. Effects of free fatty acids on human salivary gland epithelial cells. J Dent Res. 2013;92(6):540–6.PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  • Yosuke Shikama
    • 1
    Email author
  • Naozumi Ishimaru
    • 2
  • Yasusei Kudo
    • 2
  • Rieko Arakaki
    • 2
  • Yukiko Bando
    • 1
  • Nanako Aki
    • 1
  • Yoshio Hayashi
    • 2
  • Makoto Funaki
    • 1
  1. 1.Clinical Research Center for DiabetesTokushima University HospitalTokushimaJapan
  2. 2.Department of Oral Molecular Pathology, Institute of Health BiosciencesThe University of Tokushima Graduate SchoolTokushimaJapan

Personalised recommendations